S
SWTX

SignatureFD’s SpringWorks Therapeutics SWTX Stock Holding History

SignatureFD’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-134
Closed -$6.3K – 3476
2025
Q2 		$6.3K Sell
134
-17
-11% -$756 ﹤0.01% 2520
2025
Q1 		$6.66K Buy
151
+10
+7% +$460 ﹤0.01% 2504
2024
Q4 		$5.09K Buy
141
+7
+5% +$245 ﹤0.01% 2600
2024
Q3 		$4.29K Hold
134
– – ﹤0.01% 2621
2024
Q2 		$5.05K Sell
134
-9
-6% -$379 ﹤0.01% 2512
2024
Q1 		$7.04K Sell
143
-12
-8% -$555 ﹤0.01% 2436
2023
Q4 		$5.66K Buy
155
+127
+454% +$3.31K ﹤0.01% 2464
2023
Q3 		$647 Sell
28
-30
-52% -$820 ﹤0.01% 2991
2023
Q2 		$1.52K Buy
58
+30
+107% +$788 ﹤0.01% 2879
2023
Q1 		$721 Hold
28
– – ﹤0.01% 3045
2022
Q4 		$728 Sell
28
-241
-90% -$5.94K ﹤0.01% 3037
2022
Q3 		$8K Buy
269
+151
+128% +$4.33K ﹤0.01% 2207
2022
Q2 		$3K Sell
118
-60
-34% -$2.19K ﹤0.01% 2662
2022
Q1 		$10K Buy
178
+162
+1,013% +$9.27K ﹤0.01% 2173
2021
Q4 		$1K Buy
16
+5
+45% +$331 ﹤0.01% 2999
2021
Q3 		$1K Buy
+11
New +$848 ﹤0.01% 2928

Other funds holding SWTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

SignatureFD's SWTX Position: Q3 2025 in Review

SignatureFD sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 134 shares — an estimated $6.3K sold.

SignatureFD first reported a position in SWTX in Q3 2021 and held it in 16 quarters. The position peaked at $10K in Q1 2022. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

  • SignatureFD reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
  • SignatureFD sold 134 SpringWorks Therapeutics shares in Q3 2025, an estimated $6.3K.
  • SignatureFD first reported a position in SpringWorks Therapeutics in Q3 2021 and held it in 16 quarters.
  • SignatureFD's SpringWorks Therapeutics position peaked at $10K in Q1 2022.
  • 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on SignatureFD's 13F filing for Q3 2025, filed 21 Oct 2025.